Videos

RSS icon
Firas Zahr, MD,director of interventional cardiology, co-director, complex heart valve program, Oregon Health and Science University, discusses the one-year outcomes for transferral transcatheter mitral valve replacement (TMVR) in the Medtronic Intrepid Early Feasibility Study presented at TCT 2023.

Intrepid transfemoral transcatheter mitral valve shows favorable results after 1 year

Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

Matthias Götberg discusses iFR vs. FFR from the National SWEDEHEART Quality Registry at #TCT2023. #iFR

iFR and FFR are equal, new long-term analysis confirms

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

Video of Patrick McGill, MD, explaining how Community Health Network in Indiana eliminated more than 5 million nuisance alerts.

Indiana hospitals reduce nuisance alerts by 77% with medication decision support software

"Changing just six alerts in the system knocked out about 5 million alerts annually," explained Patrick McGill, MD, executive vice president and chief transformation officer at CHN.

Video of Kendra Grubb discussing transcatheter tricuspid and mitral advancements at TCT 2023.

Key trends in transcatheter tricuspid and mitral valve technologies

The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023. 

Kendra Grubb discusses TAVR vs SAVR and the most recent data to explain choices with patients.

TAVR or SAVR? Where things stand now, from a surgeon's perspective

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

Samir Kapadia, MD, Cleveland Clinic, explains the WATCH TAVR study results that combined LAAO with transcatheter aortic valve replacement at TCT 2023. #TCT2023 #TAVR #Watchman #LAAO

TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

Robert Yeh, MD, explains the details of the AGENT IDE trial clinical trial results for the Agent drug-coated balloon vs plain angioplasty for in-stent restenosis at TCT 2023. #TCT #TCT2023 #DCB

Coronary drug-coated balloon superior to standard of care for in-stent restenosis

Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis. 

Video of Michael Reardon, MD, explaining details from the Evolute Low Risk 4-year results at TCT 2023.

TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial

Michael Reardon, MD, discussed his team's late-breaking results at TCT 2023 in San Francisco. 

Displaying 305 - 312 of 569
Design by Adaptive Theme